PRDM1

Overview

PRDM1 (PR Domain Zinc Finger Protein 1), also known as BLIMP1, is a transcriptional repressor with roles in cell differentiation, particularly in B-cell and plasma cell development. PRDM1 functions as a tumor suppressor in certain lymphoid malignancies and was identified with somatic mutations in prostate cancer through whole-exome sequencing.

Alterations observed in the corpus

  • PRDM1 somatic mutations identified in prostate cancer by WES of 112 primary tumors (Broad Institute cohort) PMID:22610119
  • Recurrent missense S552C and clustered S605R/S606I hotspot mutations plus truncating/splice mutations in multiple myeloma; supports PRDM1 (BLIMP1) as a plasma-cell tumor suppressor PMID:24434212
  • In PCNSL, PRDM1 (6q21) deletion occurs in 55% of cases (homozygous in 2/18); deletion is associated with shorter overall survival in univariate analysis (log-rank P=0.001). Also recurrently mutated (somatic mutations in a subset), consistent with its role in systemic DLBCL. PMID:25991819

Cancer types (linked)

Co-occurrence and mutual exclusivity

Therapeutic relevance

  • No therapeutic agents targeting PRDM1 are described in the corpus.

Open questions

  • The frequency and functional impact of PRDM1 mutations in prostate cancer, and whether they define a distinct molecular subtype, require further characterization.

Sources

This page was processed by crosslinker on 2026-05-14. - PMID:24434212

This page was processed by crosslinker on 2026-05-14. - PMID:25991819

This page was processed by crosslinker on 2026-05-14.